Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients

Study Overview
=================
Brief Summary
-----------------
case control study to compare level of interleukin 38 in patients with psoriasis and patients with metabolic syndrome with healthy control subjects

Detailed Description
-----------------
this case control study will measure plasma level of interleukin 38 in 4 groups of 24 subject, group one will have psoriatic patients, group 2 will have psoriatic patients with metabolic syndrome, group three will have patients with metabolic syndrome only, and group 4 will have healthy control subjects.

Official Title
-----------------
Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Diagnostic Test: measure plasma level of interleukin 38 by ELISA kit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: specific to each group Exclusion Criteria: Patient refusal. Age <18 years Pregnancy Lactation smoking Infections. Patients with other inflammatory skin disorders use of antioxidant and anti-inflammatory drugs patients on treatment for psoriasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1 (Psoriasis only)<br>contains 24 psoriatic patients, Psoriasis Area Severity Index will be measured, also waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile and finally: plasma level of interleukin 38 | Diagnostic Test: measure plasma level of interleukin 38 by ELISA kit<br>* draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test<br>|
| Group 2 (Psoriasis and metabolic syndrome)<br>contains 24 psoriatic patients with metabolic syndrome. Psoriasis Area Severity Index will be measured metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38 | Diagnostic Test: measure plasma level of interleukin 38 by ELISA kit<br>* draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test<br>|
| Group 3 (Metabolic syndrome only)<br>contains 24 patients with metabolic syndrome only. full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38 | Diagnostic Test: measure plasma level of interleukin 38 by ELISA kit<br>* draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test<br>|
| Group 4 (Healthy Controls)<br>contains 24 healthy control subjects full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is excluded after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38 | Diagnostic Test: measure plasma level of interleukin 38 by ELISA kit<br>* draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measure plasma level of interleukin 38 in all groups | level of interleukin 38 will be measured and compared in all groups to asses the relationship between this interleukin and metabolic syndrome in psoriatic patients | through study completion an average of 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psoriasis, metabolic syndrome, interleukin 38